AIM ImmunoTech Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are with fiscal 2022. This is an annual report, not a standalone fourth-quarter report. AIM is a development-stage immunopharmaceutical company focused primarily on Ampligen (rintatolimod). Ampligen is not FDA-approved or marketed in the United States; it is approved in Argentina for severe chronic fatigue syndrome, but commercial distribution there remained subject to product release testing and other steps.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $202,000 | $141,000 |
| Research and development expense | $10.939 million | $6.990 million |
| General and administrative expense | $21.137 million | $13.074 million |
| Operating loss | $31.916 million | $19.923 million |
| Net loss | $28.962 million | $19.445 million |
| Basic and diluted loss per share | $0.60 | $0.40 |
| Cash used in operating activities | $21.267 million | $16.108 million |
| Cash and cash equivalents, year-end | $5.439 million | $27.053 million |
| Marketable investments, year-end | $7.631 million | $7.137 million |
| Total assets, year-end | $19.381 million | $40.488 million |
| Total liabilities, year-end | $9.147 million | $2.020 million |
Revenue came from U.S. Ampligen clinical treatment and cost-recovery programs; the company reported no Alferon N Injection finished goods available for commercial sale. Revenue remains immaterial relative to operating expenses, so operating margins are deeply negative. The filing does not provide a meaningful positive gross-margin measure.
Cash, cash equivalents and marketable investments totaled $13.070 million at year-end, down approximately $21.120 million from December 2022. Current assets were $14.556 million against current liabilities of $8.652 million. Year-end liabilities were principally accounts payable ($6.443 million), accrued expenses ($1.986 million) and operating lease obligations; the filing reports no material funded debt at year-end. Accumulated deficit was $409.508 million.
Material changes versus FY2022
- Net loss increased by $9.517 million, or approximately 49%, and loss per share widened from $0.40 to $0.60.
- R&D expense rose $3.949 million, mainly from company-sponsored clinical trials and outside consultants.
- G&A expense increased $8.063 million. Management attributed the increase primarily to approximately $6.5 million of legal fees related to shareholder matters and $2.407 million of financial consulting fees; stock compensation decreased $0.711 million.
- Operating cash use increased $5.159 million. Cash and cash equivalents fell by $21.614 million during the year.
- Investment results improved by $1.879 million, from a $1.679 million loss in 2022 to a $0.200 million gain in 2023. Interest and other income was $1.069 million, versus $0.629 million.
- The company recorded $1.667 million of gain from the sale of income tax operating losses, versus $1.490 million in 2022. It sold New Jersey tax losses and credits for approximately $1.313 million and recorded a deferred tax asset associated with 2023 losses expected to be sold in 2024.
Outlook, development programs and notable items
- Management stated that available funds were expected to support anticipated operating needs and current clinical trials for approximately 24 months. AIM does not expect material operating revenue in the near future and may require additional financing. This runway statement is management’s estimate, not a guarantee.
- After year-end, AIM reported $2.5 million in net proceeds from an unsecured promissory note issued in February 2024. On March 28, 2024, it entered an equity purchase agreement allowing, but not requiring, sales of up to $15 million of common stock to Atlas over 24 months, subject to registration and other conditions. The agreement includes share-sale limits and potential dilution. The company also had an $8.5 million Maxim equity distribution facility; 2023 sales under it generated approximately $344,000 gross.
- The Phase 2 AMP-270 pancreatic cancer study was recruiting patients at year-end. The company is also participating in a separate Erasmus MC/AstraZeneca study combining Ampligen and durvalumab; the study had opened and dosed its first subject. Earlier pancreatic cancer findings cited by AIM include historical-control comparisons and are not confirmatory randomized-trial results.
- The Phase 2 AMP-518 Post-COVID conditions study enrolled 80 participants; all had completed the study, and topline data were reported in February 2024. This 10-K does not provide the topline results.
- The FDA issued a Complete Response Letter in 2013 for AIM’s Ampligen ME/CFS application, citing insufficient evidence of efficacy and safety data concerns and requesting further work. AIM says it is developing a response and confirmatory-trial approach. Argentine commercial launch remained pending ANMAT inspection and product release testing.
- Alferon N Injection sales remain halted because the company lacks finished inventory; production is on hold with no definitive restart timetable. The company must identify a manufacturer and meet FDA requirements before sales can resume.
- Management is pursuing partnerships and co-development support. Manufacturing capacity, limited suppliers, regulatory approval, clinical-trial execution, dilution and continuing cash burn are significant risks. The company also disclosed shareholder-related litigation and is seeking insurance recovery for some legal expenses; any recovery was uncertain.
- BDO issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to audit internal control effectiveness.
Important facts for investors to verify
- Current cash, investment balances, actual monthly cash burn and the assumptions behind management’s estimated 24-month runway.
- Terms, timing, availability and dilution from the February 2024 note, Maxim facility and Atlas equity line, including registration effectiveness and any shares issued.
- AMP-518 topline findings and subsequent full results, and enrollment, costs and milestones for AMP-270 and other clinical programs.
- FDA requirements and timing for Ampligen’s U.S. development and the status of ANMAT release testing and any Argentine commercial launch.
- Resolution and potential financial exposure from litigation, including shareholder disputes and the BioLife matter, as well as any insurance reimbursement.
- Manufacturing readiness and supply availability for Ampligen, and whether Alferon N can be manufactured and returned to commercial sale.